Evogene Ltd (EVGN)

[Fress]

Float is way too small to handle the masses. Just the beginning.


Momentum building up. very high demand and very little supply only 35 million shares insiders & institutions like ARKG own over 45% of the shares.


All time high of $6.00 is pennies away then we go into uncharted territory.


this can double or triple in a blink of an eye. Quality name you want to hold for mind numbing gains.



always early..


Cathie Wood ARKG ETF picked Beam EDIT PACB gene editing stocks this one is going to exponentially grow and scale in share price and the applications for biotech green agriculture and weed markets. This has 1000% upside potential by the end of the year.


EVGN is a leading computational biology gene editing AI company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of our broadly applicable Computational Predictive Biology (CPB) platform.

EVGN Subsidiaries:
Evogene group supports independent entities focusing on a defined commercial field with an exclusive license to use our unique solution for product development.

1.Biomica
https://www.biomicamed.com/
2.Canonic
https://canonicbio.com/
3.AgPlenus
https://www.agplenus.com/
4.Lavie Bio
https://www.lavie-bio.com/
5.Castera
https://www.evogene.com/wp-content/uploads/2019/05/Casterra-company-presentation-ICOA-_pdf-version.pdf


Evogene to Participate in CRISPR-IL Consortium to Provide End-to-End Artificial Intelligence System for Genome-Editing

Evogene's work in the consortium is expected to include the broadening of its artificial intelligence capabilities that are expected to extend the range of its GENErator AI solution (part of Evogene's CPB platform). Evogene's GENErator AI solution already includes computational capabilities directing "which" edit should be made to achieve a specific trait; and the capabilities developed within the framework of the consortium aim to improve "how" these edits are made.
https://www.prnewswire.com/il/news-releases/evogene-to-participate-in-crispr-il-consortium-to-provide-end-to-end-artificial-intelligence-system-for-genome-editing-301069960.html



Genome Stocks-Gene Editing.
$PACB 6.2 billion market cap
$BEAM 5.4 billion market cap
$CRSP 13 billion market cap
$EDIT 4.8 billion market cap
$SGMO 2.3 billion market cap
$NTLA 4.8 billion market cap
$BLUE 3.3 billion market cap
$BNGO 1.2 billion market cap
$EVGN 200 million market cap 35 million shares 45% owned by institutions & insiders


EVGN website:
https://www.evogene.com/

Boomage Weeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeeee
https://mma-user-upload.mixedmartialarts.com/2020-09/tenor%20(8).gif


$EVGN